Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage II Bladder Urothelial Carcinoma AJCC v6 and v7”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Study completedNCT03421652
What this trial is testing

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Who this might be right for
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7
Barbara Ann Karmanos Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT02844816
What this trial is testing

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder Urothelial CarcinomaStage 0a Bladder Urothelial Carcinoma AJCC v6 and v7Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7+1 more
National Cancer Institute (NCI) 172
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 132
Large-scale testing (Phase 3)Looking for participantsNCT05987241
What this trial is testing

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Who this might be right for
Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial Carcinoma+4 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT03244384
What this trial is testing

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Who this might be right for
Localized Renal Pelvis and Ureter Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial Carcinoma+8 more
National Cancer Institute (NCI) 739
Very early researchActive Not RecruitingNCT02812420
What this trial is testing

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Who this might be right for
HydronephrosisInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary Variant+16 more
M.D. Anderson Cancer Center 54
Testing effectiveness (Phase 2)WithdrawnNCT03419130
What this trial is testing

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

Who this might be right for
Infiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
University of California, San Francisco
Testing effectiveness (Phase 2)Study completedNCT02178241
What this trial is testing

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Ureter CarcinomaMetastatic Urethral CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7+7 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03047213
What this trial is testing

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaMetastatic Transitional Cell CarcinomaMetastatic Urothelial Carcinoma+3 more
National Cancer Institute (NCI) 17
Testing effectiveness (Phase 2)Study completedNCT00238420
What this trial is testing

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v6 and v7Stage II Bladder Cancer AJCC v6 and v7+1 more
National Cancer Institute (NCI) 70
992